Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants

Area of Science:

• Virology and Immunology
• Structural Biology
• Computational Biology

Background:

• SARS-CoV-2 evolution, especially Omicron subvariants, has reduced the efficacy of existing therapeutic antibodies.
• The development of broadly effective antibody therapies is crucial to combat viral antigenic drift.

Purpose of the Study:

• To optimize the COV2-2196 antibody for enhanced neutralization of SARS-CoV-2 Omicron variants using structure-guided computational design.
• To identify specific mutations that restore and improve antibody binding and potency against resistant strains.

Main Methods:

• Employed iterative structure-guided computational design and experimental validation.
• Utilized cryo-electron microscopy (Cryo-EM) for structural analysis.
• Focused on optimizing the antibody's paratope to accommodate viral epitope changes.

Main Results:

• Identified key paratope mutations that significantly restored and enhanced COV2-2196 binding and neutralization against Omicron variants.
• Cryo-EM revealed the molecular mechanisms underlying the improved antibody efficacy.
• Demonstrated the feasibility of using accessible computational resources for antibody optimization.

Conclusions:

• Structure-based computational design is an effective strategy for rapidly optimizing therapeutic antibodies against evolving viruses like SARS-CoV-2.
• Targeted antibody modifications can overcome viral immune escape mechanisms.
• This approach provides a practical framework for developing broadly effective antibody therapeutics for emerging infectious diseases.